Review of emerging treatments for age-related macular degeneration

Marco A. Zarbin, Philip J Rosenfeld

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

In the era of pathway-based therapy, all treatments for AMD will address some step in the pathway that leads from early to late AMD. Steps in AMD pathogenesis that appear to be good targets for drug development include the following: (1) oxidative damage, (2) lipofuscin accumulation, (3) chronic inflammation, (4) mutations in the complement pathway, (5) mitochondrial damage, (6) Alu RNA accumulation in RPE, and (7) BMP-4 accumulation in RPE. Steps in neovascularization that can be targeted for drug development and combination therapy include the following: (1) angiogenic factor production, (2) extracellular factor release, (3) binding of factors to extracellular receptors (and activation of intracellular signaling after receptor binding), (4) endothelial cell activation (and basement membrane degradation), (5) endothelial cell proliferation, (6) directed endothelial cell migration, (7) extracellular matrix remodeling, (8) tube formation, and (9) vascular stabilization. Combination therapy will likely supplant monotherapy as the treatment of choice because the clinical benefits will likely be superior in preventing the complications of AMD.

Original languageEnglish (US)
Title of host publicationStudies on Retinal and Choroidal Disorders
PublisherHumana Press Inc.
Pages1-46
Number of pages46
ISBN (Electronic)9781617796067
ISBN (Print)9781617796050
DOIs
StatePublished - Jan 1 2012

Fingerprint

Endothelial cells
Macular Degeneration
Endothelial Cells
Chemical activation
Bone Morphogenetic Protein 7
Lipofuscin
Angiogenesis Inducing Agents
Complement C5
Cell proliferation
Pharmaceutical Preparations
Therapeutics
Stabilization
Combination Drug Therapy
Basement Membrane
RNA
Cell Movement
Extracellular Matrix
Blood Vessels
Degradation
Cell Proliferation

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Zarbin, M. A., & Rosenfeld, P. J. (2012). Review of emerging treatments for age-related macular degeneration. In Studies on Retinal and Choroidal Disorders (pp. 1-46). Humana Press Inc.. https://doi.org/10.1007/978-1-61779-606-7_1

Review of emerging treatments for age-related macular degeneration. / Zarbin, Marco A.; Rosenfeld, Philip J.

Studies on Retinal and Choroidal Disorders. Humana Press Inc., 2012. p. 1-46.

Research output: Chapter in Book/Report/Conference proceedingChapter

Zarbin, MA & Rosenfeld, PJ 2012, Review of emerging treatments for age-related macular degeneration. in Studies on Retinal and Choroidal Disorders. Humana Press Inc., pp. 1-46. https://doi.org/10.1007/978-1-61779-606-7_1
Zarbin MA, Rosenfeld PJ. Review of emerging treatments for age-related macular degeneration. In Studies on Retinal and Choroidal Disorders. Humana Press Inc. 2012. p. 1-46 https://doi.org/10.1007/978-1-61779-606-7_1
Zarbin, Marco A. ; Rosenfeld, Philip J. / Review of emerging treatments for age-related macular degeneration. Studies on Retinal and Choroidal Disorders. Humana Press Inc., 2012. pp. 1-46
@inbook{ebcb71941c9e4d5497db3360c56d7886,
title = "Review of emerging treatments for age-related macular degeneration",
abstract = "In the era of pathway-based therapy, all treatments for AMD will address some step in the pathway that leads from early to late AMD. Steps in AMD pathogenesis that appear to be good targets for drug development include the following: (1) oxidative damage, (2) lipofuscin accumulation, (3) chronic inflammation, (4) mutations in the complement pathway, (5) mitochondrial damage, (6) Alu RNA accumulation in RPE, and (7) BMP-4 accumulation in RPE. Steps in neovascularization that can be targeted for drug development and combination therapy include the following: (1) angiogenic factor production, (2) extracellular factor release, (3) binding of factors to extracellular receptors (and activation of intracellular signaling after receptor binding), (4) endothelial cell activation (and basement membrane degradation), (5) endothelial cell proliferation, (6) directed endothelial cell migration, (7) extracellular matrix remodeling, (8) tube formation, and (9) vascular stabilization. Combination therapy will likely supplant monotherapy as the treatment of choice because the clinical benefits will likely be superior in preventing the complications of AMD.",
author = "Zarbin, {Marco A.} and Rosenfeld, {Philip J}",
year = "2012",
month = "1",
day = "1",
doi = "10.1007/978-1-61779-606-7_1",
language = "English (US)",
isbn = "9781617796050",
pages = "1--46",
booktitle = "Studies on Retinal and Choroidal Disorders",
publisher = "Humana Press Inc.",

}

TY - CHAP

T1 - Review of emerging treatments for age-related macular degeneration

AU - Zarbin, Marco A.

AU - Rosenfeld, Philip J

PY - 2012/1/1

Y1 - 2012/1/1

N2 - In the era of pathway-based therapy, all treatments for AMD will address some step in the pathway that leads from early to late AMD. Steps in AMD pathogenesis that appear to be good targets for drug development include the following: (1) oxidative damage, (2) lipofuscin accumulation, (3) chronic inflammation, (4) mutations in the complement pathway, (5) mitochondrial damage, (6) Alu RNA accumulation in RPE, and (7) BMP-4 accumulation in RPE. Steps in neovascularization that can be targeted for drug development and combination therapy include the following: (1) angiogenic factor production, (2) extracellular factor release, (3) binding of factors to extracellular receptors (and activation of intracellular signaling after receptor binding), (4) endothelial cell activation (and basement membrane degradation), (5) endothelial cell proliferation, (6) directed endothelial cell migration, (7) extracellular matrix remodeling, (8) tube formation, and (9) vascular stabilization. Combination therapy will likely supplant monotherapy as the treatment of choice because the clinical benefits will likely be superior in preventing the complications of AMD.

AB - In the era of pathway-based therapy, all treatments for AMD will address some step in the pathway that leads from early to late AMD. Steps in AMD pathogenesis that appear to be good targets for drug development include the following: (1) oxidative damage, (2) lipofuscin accumulation, (3) chronic inflammation, (4) mutations in the complement pathway, (5) mitochondrial damage, (6) Alu RNA accumulation in RPE, and (7) BMP-4 accumulation in RPE. Steps in neovascularization that can be targeted for drug development and combination therapy include the following: (1) angiogenic factor production, (2) extracellular factor release, (3) binding of factors to extracellular receptors (and activation of intracellular signaling after receptor binding), (4) endothelial cell activation (and basement membrane degradation), (5) endothelial cell proliferation, (6) directed endothelial cell migration, (7) extracellular matrix remodeling, (8) tube formation, and (9) vascular stabilization. Combination therapy will likely supplant monotherapy as the treatment of choice because the clinical benefits will likely be superior in preventing the complications of AMD.

UR - http://www.scopus.com/inward/record.url?scp=84925853657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925853657&partnerID=8YFLogxK

U2 - 10.1007/978-1-61779-606-7_1

DO - 10.1007/978-1-61779-606-7_1

M3 - Chapter

AN - SCOPUS:84925853657

SN - 9781617796050

SP - 1

EP - 46

BT - Studies on Retinal and Choroidal Disorders

PB - Humana Press Inc.

ER -